臨床試験市場：フェーズ（フェーズI、II、III）、サービスタイプ（施設確認、ラボサービス、分散型臨床試験）、治療領域（腫瘍、感染症）、アプリケーション（ワクチン、細胞・遺伝子治療）別 - 2026年までの世界予測

Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026

臨床試験市場は、臨床試験数の増加、希少疾病の増加、自社薬剤開発の高コストなどを背景に、2021年の387億米ドルから2026年にはCAGR6.1％で520億米ドルに達すると予測されています。 "サービスタイプ別では、ラ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年2月21日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	306	383	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

臨床試験市場は、臨床試験数の増加、希少疾病の増加、自社薬剤開発の高コストなどを背景に、2021年の387億米ドルから2026年にはCAGR6.1％で520億米ドルに達すると予測されています。
"サービスタイプ別では、ラボラトリーサービス分野が臨床試験市場で最大のシェアを占めている"
臨床試験市場は、サービスの種類によって、プロトコル設計、施設特定、患者募集、ラボサービス、生物学的分析試験、分析試験、臨床試験供給・物流サービス、分散型臨床サービス、臨床試験データ管理サービス、医療機器試験サービス、その他のサービスに区分されます。ラボサービスは臨床試験サービス市場の主要セグメントであり、これは臨床研究専門家がこうしたサービスのアウトソーシングを好むようになっていることに起因しています。
「アジア太平洋地域。臨床試験市場で最も成長率の高い地域"
アジア太平洋地域は、予測期間中に最も高いCAGRで成長すると予測されています。この地域の高い成長率は、同地域で急成長する製薬業界、有利な政府政策、同地域に製造施設を設立する製薬会社の増加、同地域の臨床試験費用の低さなどに起因すると考えられます。

"北米 "です。北米地域は臨床試験市場で最大のシェアを占めている"
北米は臨床試験市場で最大のシェアを占めています。バイオシミラーや生物製剤市場の急成長と臨床試験活動の活発化が市場成長の主な要因となっています。
プライマリーの内訳

本調査には、部品サプライヤーからティア1企業、OEMに至るまで、様々な業界専門家による洞察が含まれています。プライマリーの内訳は以下の通りです。
回答者別 - 供給サイド - 40%, 需要サイド - 60
役職別 - 役員 - 25%、CXOおよび取締役 - 30%、管理職 - 45
地域別 - 北米 40%、欧州 25%、APAC 20%、LATAM 10%、MEA 5
臨床試験市場は、IQVIA（米国）、LabCorp（米国）、Charles River Laboratories（米国）、WuXi AppTec（中国）、Synos Health（米国）、Parexel International（米国）、PPD（米国）、ICON Plc（米国）など、少数の世界的なプレーヤーによって独占されています。その他、Medpace Holdings（米国）、SGS（スイス）、PSI CRO AG（米国）、Axcent Advanced Analytics（米国）、BIO Agile Therapeutics（米国）、Firma Clinical Research（米国）、Acculab Life Sciences（米国）、Azerix（米国）、CTserv（米国）、Pepgra（英国）およびDove Quality Solutions（米国）、Novotech Health Holding（オーストラリア）、Jetricist Inc.(米国）、Linical Americas（米国）、Frontage Holding Corporation（米国）、Celerion（米国）です。

研究対象。

本レポートでは、臨床試験市場を地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）、フェーズ（フェーズI、フェーズII、フェーズIII、フェーズIV）、サービスタイプ（プロトコル設計、施設特定、患者募集、ラボサービス、バイオ分析試験サービス（セルベースアッセイ、ウイルス試験、メソッド開発、最適化・検証、血清学、免疫原性、中和抗体、バイオマーカー試験サービス）に基づいてセグメントしています。PK/PD試験サービス、その他のバイオ分析試験サービス）、分析試験サービス、治験薬供給・物流サービス、分散型臨床サービス、治験データ管理サービス、医療機器試験サービス、その他の治験サービス）、治療領域（がん、感染症、循環器、神経、女性健康、遺伝子疾患、免疫、その他の治療領域）、アプリケーション（ワクチン、細胞・遺伝子治療、低分子、その他のアプリケーション）。
また、臨床試験市場における市場の促進要因、課題、機会についても包括的にレビューしています。
レポート購入の主なメリット

このレポートは、この市場のリーダー/新規参入者に、市場全体とサブセグメントの収益数の最も近い近似値に関する情報を提供するものです。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは臨床試験市場の鼓動を理解し、主要な市場促進要因、課題、機会に関する情報を関係者に提供するのに役立ちます。

ページTOPに戻る

Table of Contents

Summary

The clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period, owing to increasing number of clinical trials, rising prevalence of orphan & rare diseases and high cost of in-house drug development.
“By service type, the laboratory services segment accounted for the largest share of the clinical trials market”
Based on service type, the clinical trials market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. Laboratory services is the leading segment of clinical trial services market, this can be attributed to the increasing preference of clinical research professionals to outsource such services.
“Asia Pacific: The fastest-growing region in the clinical trials market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high growth rate in this region can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, the increasing number of pharmaceutical companies establishing manufacturing facilities in the region, and the lower cost of clinical trials in the region.

“North America: The North America region accounted for the largest share of the clinical trials market”
North America accounted for the largest share of the clinical trials market. Rapid growth in the biosimilar and biologics markets and an increase in clinical trial activity are the major factors driving the market growth.
Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
By Respondent– Supply Side- 40%, Demand Side- 60%
By Designation— Executives- 25%, CXOs & Directors--30%, Managers - 45%
By Region— North America - 40%, Europe - 25%, APAC – 20%, LATAM- 10%, MEA- 5%
The clinical trials market is dominated by a few globally established players such as including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), and ICON Plc (US). Other players operating in the market are Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US).

Research Coverage:

The report segments the clinical trials market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), Phase (Phase I, Phase II, Phase III, Phase IV), Service Type (Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services (Cell-based Assays, Virology Testing, Method Development, Optimization & Validation, Serology, Immunogenicity, & Neutralizing Antibodies, Biomarker Testing Services, PK/PD Testing Services, Other Bioanalytical Testing Services), Analytical Testing Services, Clinical Trial Supply & Logistic Services, Decentralized Clinical Services, Clinical Trial Data Management Services, Medical Device Testing Services, Other Clinical Trial Services), Therapy Area (Oncology, Infectious Diseases, Cardiology, Neurology, Women's Health, Genetic Diseases, Immunology, and Other Therapy Areas), Application (Vaccine, Cell & Gene Therapy, Small Molecules, Other Applications)
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the clinical trials market.
Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the clinical trials market and provides them information on key market drivers, challenges, and opportunities.

ページTOPに戻る

1 INTRODUCTION 40

1.1 OBJECTIVES OF THE STUDY 40

1.2 MARKET DEFINITION 40

1.2.1 INCLUSIONS & EXCLUSIONS 40

1.3 MARKET SCOPE 41

FIGURE 1 CLINICAL TRIALS MARKET 41

1.3.1 YEARS CONSIDERED FOR THE STUDY 42

1.4 CURRENCY 42

1.5 LIMITATIONS 42

1.6 STAKEHOLDERS 43

1.7 SUMMARY OF CHANGES 43

2 RESEARCH METHODOLOGY 44

2.1 RESEARCH DATA 44

FIGURE 2 RESEARCH DESIGN 44

2.1.1 SECONDARY DATA 45

2.1.2 PRIMARY DATA 46

FIGURE 3 CLINICAL TRIALS MARKET: BREAKDOWN OF PRIMARIES 46

2.2 MARKET SIZE ESTIMATION 47

FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET 47

FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020 48

FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020 48

2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 50

FIGURE 7 CLINICAL TRIALS MARKET: CAGR PROJECTIONS, 2021–2026 50

FIGURE 8 CLINICAL TRIALS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES 51

FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 51

2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 53

FIGURE 10 DATA TRIANGULATION METHODOLOGY 53

2.5 INSIGHTS FROM PRIMARIES 54

FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 54

2.6 RESEARCH ASSUMPTIONS 54

2.6.1 COVID-19 SPECIFIC ASSUMPTIONS 55

2.7 RISK ANALYSIS 55

3 EXECUTIVE SUMMARY 56

FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026 (USD BILLION) 56

FIGURE 13 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2021 VS. 2026 (USD BILLION) 57

FIGURE 14 CLINICAL TRIALS MARKET, BY APPLICATION, 2021 VS. 2026 (USD BILLION) 57

FIGURE 15 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2021 VS. 2026 (USD BILLION) 58

FIGURE 16 GEOGRAPHICAL SNAPSHOT: CLINICAL TRIALS MARKET 59

4 PREMIUM INSIGHTS 60

4.1 CLINICAL TRIALS MARKET OVERVIEW 60

FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE

THE MARKET GROWTH 60

4.2 NORTH AMERICA: CLINICAL TRIALS MARKET SHARE, BY PHASE & COUNTRY (2020) 61

FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CLINICAL TRIALS MARKET IN 2020 61

4.3 CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICE TYPE,

2021 VS. 2026 (USD BILLION) 62

FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 62

5 MARKET OVERVIEW 63

5.1 INTRODUCTION 63

5.2 MARKET DYNAMICS 63

FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63

TABLE 1 CLINICAL TRIALS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64

5.2.1 DRIVERS 64

5.2.1.1 Increasing investment in pharmaceutical R&D 64

FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 65

FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 65

5.2.1.2 Increasing number of clinical trials 66

FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021) 66

5.2.1.3 High cost of in-house drug development 66

FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 67

5.2.1.4 Rising prevalence of orphan and rare diseases 67

5.2.2 OPPORTUNITIES 68

5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic 68

FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020) 68

TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020 68

5.2.2.2 Rising demand for specialized testing services among end users 69

5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies 70

5.2.3 CHALLENGES 70

5.2.3.1 Shortage of skilled professionals for clinical trials 70

5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules 70

5.2.4 MARKET TRENDS 71

5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery 71

5.2.4.2 Increasing outsourcing activities in emerging Asian economies 71

5.2.4.3 Integrated end-to-end R&D service solutions 73

5.3 RANGES/SCENARIOS 73

FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE CLINICAL TRIALS MARKET 73

5.4 IMPACT OF COVID-19 ON CLINICAL TRIALS MARKET 74

5.5 PORTER’S FIVE FORCES ANALYSIS 75

TABLE 3 CLINICAL TRIALS MARKET: PORTER’S FIVE FORCES ANALYSIS 75

5.5.1 THREAT OF NEW ENTRANTS 75

5.5.2 THREAT OF SUBSTITUTES 75

5.5.3 BARGAINING POWER OF BUYERS 75

5.5.4 BARGAINING POWER OF SUPPLIERS 76

5.5.5 DEGREE OF COMPETITION 76

5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76

FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 76

5.7 ECOSYSTEM ANALYSIS 77

FIGURE 28 ECOSYSTEM ANALYSIS: CLINICAL TRIALS MARKET 77

TABLE 4 SUPPLY CHAIN ECOSYSTEM 78

5.8 REGULATORY ANALYSIS 79

6 CLINICAL TRIALS MARKET, BY PHASE 82

6.1 INTRODUCTION 83

TABLE 5 CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 83

FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020 84

6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION 84

FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING 84

6.3 PHASE I 87

6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT 87

TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS 87

TABLE 7 PHASE I CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 88

TABLE 8 NORTH AMERICA: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 88

TABLE 9 EUROPE: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 88

TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 89

6.4 PHASE II 89

6.4.1 LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS 89

TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES 89

TABLE 12 PHASE II CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 90

TABLE 13 NORTH AMERICA: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 90

TABLE 14 EUROPE: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 91

TABLE 15 ASIA PACIFIC: PHASE II CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 91

6.5 PHASE III 92

6.5.1 RISING COSTS OF PHASE III TRIALS INCREASES THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES 92

TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY 92

TABLE 17 PHASE III CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 93

TABLE 18 NORTH AMERICA: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 93

TABLE 19 EUROPE: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 93

TABLE 20 ASIA PACIFIC: PHASE III CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 94

6.6 PHASE IV 94

6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH 94

TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES 94

TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 95

TABLE 23 NORTH AMERICA: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 95

TABLE 24 EUROPE: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 95

TABLE 25 ASIA PACIFIC: PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 96

7 CLINICAL TRIALS MARKET, BY SERVICE TYPE 97

7.1 INTRODUCTION 98

TABLE 26 CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 98

7.2 PROTOCOL DESIGNING 99

7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES 99

TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019–2026 (USD BILLION) 99

TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 100

TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 100

TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 100

7.3 SITE IDENTIFICATION 101

7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY 101

TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019–2026 (USD BILLION) 101

TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 102

TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 102

TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 102

7.4 PATIENT RECRUITMENT 103

7.4.1 GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT 103

TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS 103

TABLE 36 PATIENT RECRUITEMENT MARKET, BY REGION, 2019–2026 (USD BILLION) 104

TABLE 37 NORTH AMERICA: PATIENT RECRUITEMENT MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 104

TABLE 38 EUROPE: PATIENT RECRUITEMENT MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 104

TABLE 39 ASIA PACIFIC: PATIENT RECRUITEMENT MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 105

7.5 LABORATORY SERVICES 105

7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT 105

TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 105

TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION) 106

TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 106

TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 107

TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 107

7.5.2 ANALYTICAL TESTING SERVICES 107

7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment 107

TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 108

TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 108

TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 108

TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 109

7.6 BIOANALYTICAL TESTING SERVICES 109

7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT 109

TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE,

2019–2026 (USD BILLION) 110

TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 110

TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 110

TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 111

TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 111

7.6.2 CELL-BASED ASSAYS 111

7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment 111

TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD BILLION) 112

TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 112

TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 112

TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 113

7.6.3 VIROLOGY TESTING 113

7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment 113

TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019–2026 (USD BILLION) 113

TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 114

TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 114

TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 114

7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES 115

7.6.4.1 Rising importance of studies to determine pharmacokinetic behavior of drug candidates to drive the growth of this segment 115

TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION) 115

TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116

TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116

TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 116

7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION 117

7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment 117

TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET,

BY REGION, 2019–2026 (USD BILLION) 117

TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118

TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118

TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 118

7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES 119

7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth 119

TABLE 70 SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET,

BY REGION, 2019–2026 (USD BILLION) 119

TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120

TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120

TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEURTALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 120

7.6.7 BIOMARKER TESTING SERVICES 121

7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth 121

TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 121

TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 121

TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 122

TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 122

7.6.8 OTHER BIOANALYTICAL TESTING SERVICES 122

TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 123

TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 123

TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 123

TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 124

7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES 124

7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD

THE HIGHEST CAGR DURING THE FORECAST PERIOD 124

TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 124

TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 125

TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 126

TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 126

TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 126

7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES 127

7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 127

TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 127

TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 127

TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 128

TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 128

7.9 DECENTRALIZED CLINICAL TRIAL SERVICES 128

7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS 128

TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 129

TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 129

TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 129

TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 130

7.10 MEDICAL DEVICE TESTING SERVICES 130

7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET 130

TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 131

TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET,

BY COUNTRY, 2019–2026 (USD BILLION) 131

TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 131

TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 132

7.11 OTHER CLINICAL TRIAL SERVICES 132

7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES 132

TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION,

2019–2026 (USD BILLION) 133

TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 133

TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 133

TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION) 134

8 CLINICAL TRIALS MARKET, BY THERAPY AREA 135

8.1 INTRODUCTION 136

TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026 (USD BILLION) 136

8.2 ONCOLOGY 136

8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 136

FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020) 137

FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND) 138

TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020) 138

TABLE 105 CLINICAL TRIALS MARKET FOR ONCOLOGY, BY REGION,

2019–2026 (USD BILLION) 139

TABLE 106 NORTH AMERICA: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 139

TABLE 107 EUROPE: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY,

2019–2026 (USD BILLION) 140

TABLE 108 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 140

8.3 INFECTIOUS DISEASES 140

8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 140

TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION,

2019–2026 (USD BILLION) 141

TABLE 110 NORTH AMERICA: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2019–2026 (USD BILLION) 141

TABLE 111 EUROPE: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2019–2026 (USD BILLION) 142

TABLE 112 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2019–2026 (USD BILLION) 142

8.4 NEUROLOGY 142

8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 142

TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020) 143

TABLE 114 CLINICAL TRIALS MARKET FOR NEUROLOGY, BY REGION,

2019–2026 (USD BILLION) 144

TABLE 115 NORTH AMERICA: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 144

TABLE 116 EUROPE: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY,

2019–2026 (USD BILLION) 144

TABLE 117 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 145

8.5 IMMUNOLOGY 145

8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES 145

TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION,

2019–2026 (USD BILLION) 145

TABLE 119 NORTH AMERICA: CLINICAL TRIALS MARKET FOR IMMUNOLOGY,

BY COUNTRY, 2019–2026 (USD BILLION) 146

TABLE 120 EUROPE: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY,

2019–2026 (USD BILLION) 146

TABLE 121 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 146

8.6 CARDIOLOGY 147

8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS 147

TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 147

TABLE 123 CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY REGION,

2019–2026 (USD BILLION) 148

TABLE 124 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 148

TABLE 125 EUROPE: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY,

2019–2026 (USD BILLION) 148

TABLE 126 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD BILLION) 149

8.7 GENETIC DISEASES 149

8.7.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH 149

TABLE 127 CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY REGION,

2019–2026 (USD BILLION) 150

TABLE 128 NORTH AMERICA: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,

BY COUNTRY, 2019–2026 (USD BILLION) 150

TABLE 129 EUROPE: CLINICAL TRIALS MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026 (USD BILLION) 150

TABLE 130 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR GENETIC DISEASES,

BY COUNTRY, 2019–2026 (USD BILLION) 151

8.8 WOMEN’S HEALTH 151

8.8.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO DRIVE MARKET GROWTH 151

TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION,

2019–2026 (USD BILLION) 151

TABLE 132 NORTH AMERICA: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,

BY COUNTRY, 2019–2026 (USD BILLION) 152

TABLE 133 EUROPE: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026 (USD BILLION) 152

TABLE 134 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH,

BY COUNTRY, 2019–2026 (USD BILLION) 152

8.9 OTHER THERAPY AREAS 153

FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,

2000-2045 (MILLION) 153

TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020) 154

TABLE 136 CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS, BY REGION,

2019–2026 (USD BILLION) 154

TABLE 137 NORTH AMERICA: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,

BY COUNTRY, 2019–2026 (USD BILLION) 155

TABLE 138 EUROPE: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,

BY COUNTRY, 2019–2026 (USD BILLION) 155

TABLE 139 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR OTHER THERAPY AREAS,

BY COUNTRY, 2019–2026 (USD BILLION) 155

9 CLINICAL TRIALS MARKET, BY APPLICATION 156

9.1 INTRODUCTION 157

TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 157

9.2 SMALL MOLECULE 157

9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS

THE GROWTH OF THIS SEGMENT 157

FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019 158

TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION,

2019–2026 (USD BILLION) 158

TABLE 142 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION) 159

TABLE 143 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026 (USD BILLION) 159

TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2019–2026 (USD BILLION) 159

9.3 VACCINES 160

9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON

THE INDUSTRY OPERATIONS 160

FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT,

BY PHASE (AS OF JANUARY 2022) 161

TABLE 145 CLINICAL TRIALS MARKET FOR VACCINES, BY REGION,

2019–2026 (USD BILLION) 161

TABLE 146 NORTH AMERICA: CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 161

TABLE 147 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 162

TABLE 148 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD BILLION) 162

9.4 CELL & GENE THERAPY 162

9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND THEIR RESPECTIVE OFFERINGS IS DRIVING THE CLINICAL DEVELOPMENT PIPELINE FOR CELL & GENE THERAPY 162

FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY,

BY INDICATION (AS OF 2020) 163

FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020) 164

TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION,

2019–2026 (USD BILLION) 164

TABLE 150 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165

TABLE 151 EUROPE: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165

TABLE 152 ASIA PACIFIC: CLINICAL TRIALS MARKET FORCLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026 (USD BILLION) 165

9.5 OTHER APPLICATIONS 166

9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH 166

TABLE 153 CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD BILLION) 166

TABLE 154 NORTH AMERICA: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167

TABLE 155 EUROPE: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167

TABLE 156 ASIA PACIFIC: CLINICAL TRIALS MARKET FOR CLINICAL TRIALS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION) 167

10 CLINICAL TRIALS MARKET, BY REGION 168

10.1 INTRODUCTION 169

TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019–2026 (USD BILLION) 169

10.2 NORTH AMERICA 169

FIGURE 38 NORTH AMERICA SNAPSHOT 170

TABLE 158 NORTH AMERICA: CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 170

TABLE 159 NORTH AMERICA: CLINICAL TRIALS MARKET, BY PHASE,

2019–2026 (USD BILLION) 171

TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,

BY SERVICE TYPE, 2019–2026 (USD BILLION) 171

TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET,

BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 172

TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET,

BY THERAPY AREA, 2019–2026 (USD BILLION) 172

TABLE 163 NORTH AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 173

10.2.1 US 173

10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth 173

FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES

BY REGION (2020 VS. 2019) 174

TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 174

TABLE 165 US: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 175

TABLE 166 US: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 175

TABLE 167 US: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 176

TABLE 168 US: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 176

10.2.2 CANADA 176

10.2.2.1 Increasing number of clinical trials in Canada to support market growth 176

TABLE 169 CANADA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 177

TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 177

TABLE 171 CANADA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 178

TABLE 172 CANADA: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 178

TABLE 173 CANADA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 179

10.3 EUROPE 179

FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018) 180

TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 180

TABLE 175 EUROPE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 180

TABLE 176 EUROPE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 181

TABLE 177 EUROPE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 181

TABLE 178 EUROPE: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 182

TABLE 179 EUROPE: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 182

10.3.1 GERMANY 182

10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials 182

TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 183

TABLE 181 GERMANY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 183

TABLE 182 GERMANY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 184

TABLE 183 GERMANY: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 184

TABLE 184 GERMANY: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 185

10.3.2 UK 185

10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth 185

FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017 (USD MILLION) 186

TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 186

TABLE 186 UK: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026 (USD BILLION) 187

TABLE 187 UK: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 187

TABLE 188 UK: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 188

TABLE 189 UK: CLINICAL TRIALS MARKET, BY APPLICATION, 2019–2026 (USD BILLION) 188

10.3.3 FRANCE 188

10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France 188

TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 189

TABLE 191 FRANCE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 189

TABLE 192 FRANCE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 190

TABLE 193 FRANCE: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 190

TABLE 194 FRANCE: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 191

10.3.4 ITALY 191

10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth 191

TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) 191

TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 192

TABLE 197 ITALY: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 192

TABLE 198 ITALY: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 193

TABLE 199 ITALY: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 193

TABLE 200 ITALY: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 194

10.3.5 SPAIN 194

10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials

in Spain 194

FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011–2017 195

TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 195

TABLE 202 SPAIN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 196

TABLE 203 SPAIN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 196

TABLE 204 SPAIN: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 197

TABLE 205 SPAIN: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 197

10.3.6 REST OF EUROPE (ROE) 198

TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 199

TABLE 207 ROE: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 199

TABLE 208 ROE: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 200

TABLE 209 ROE: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 200

TABLE 210 ROE: CLINICAL TRIALS MARKET, BY MOLECULE, 2019–2026 (USD BILLION) 201

10.4 ASIA PACIFIC (APAC) 201

FIGURE 43 ASIA PACIFIC SNAPSHOT 202

TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY,

2019–2026 (USD BILLION) 202

TABLE 212 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY PHASE,

2019–2026 (USD BILLION) 203

TABLE 213 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 203

TABLE 214 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 204

TABLE 215 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 204

TABLE 216 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 205

10.4.1 CHINA 205

10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and presence of prominent clinical trial service providers 205

TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 206

TABLE 218 CHINA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 206

TABLE 219 CHINA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 207

TABLE 220 CHINA: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 207

TABLE 221 CHINA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 208

10.4.2 JAPAN 208

10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth 208

TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,

2017 VS. 2019 208

TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 209

TABLE 224 JAPAN: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 209

TABLE 225 JAPAN: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 210

TABLE 226 JAPAN: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 210

TABLE 227 JAPAN: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 211

10.4.3 INDIA 211

10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trails 211

TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA,

2017 VS. 2019 211

TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 212

TABLE 230 INDIA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 212

TABLE 231 INDIA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 213

TABLE 232 INDIA: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 213

TABLE 233 INDIA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 214

10.4.4 REST OF ASIA PACIFIC 214

TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA,

BY THERAPEUTIC AREA, 2017 VS. 2019 214

TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 215

TABLE 236 ROAPAC: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 215

TABLE 237 ROAPAC: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 216

TABLE 238 ROAPAC: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 216

TABLE 239 ROAPAC: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 217

10.5 LATIN AMERICA 217

10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET

GROWTH IN LATIN AMERICA 217

TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE,

2019–2026 (USD BILLION) 218

TABLE 241 LATIN AMERICA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 218

TABLE 242 LATIN AMERICA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES, 2019–2026 (USD BILLION) 219

TABLE 243 LATIN AMERICA: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 219

TABLE 244 LATIN AMERICA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 220

10.6 MIDDLE EAST & AFRICA 220

10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA 220

TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026 (USD BILLION) 221

TABLE 246 MEA: CLINICAL TRIALS MARKET, BY SERVICE TYPE,

2019–2026 (USD BILLION) 221

TABLE 247 MEA: CLINICAL TRIALS MARKET, BY BIOANALYTICAL SERVICES,

2019–2026 (USD BILLION) 222

TABLE 248 MEA: CLINICAL TRIALS MARKET, BY THERAPY AREA,

2019–2026 (USD BILLION) 222

TABLE 249 MEA: CLINICAL TRIALS MARKET, BY APPLICATION,

2019–2026 (USD BILLION) 223

11 COMPETITIVE LANDSCAPE 224

11.1 INTRODUCTION 224

11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 224

FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED 225

11.3 MARKET SHARE ANALYSIS 226

FIGURE 45 CLINICAL TRIALS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020) 226

11.4 COMPANY EVALUATION QUADRANT 228

11.4.1 STARS 228

11.4.2 EMERGING LEADERS 228

11.4.3 PERVASIVE PLAYERS 228

11.4.4 PARTICIPANTS 228

FIGURE 46 CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX, 2020 229

11.5 COMPETITIVE BENCHMARKING 230

11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES) 230

FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET 230

11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 231

FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE CLINICAL TRIALS MARKET 231

11.6 COMPETITIVE SCENARIO AND TRENDS 232

11.6.1 SERVICES LAUNCHES 232

TABLE 250 CLINICAL TRIALS MARKET: SERVICE LAUNCHES

(JANUARY 2017-NOVEMBER 2020) 232

11.6.2 DEALS 233

TABLE 251 CLINICAL TRIALS MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021) 233

11.6.3 OTHER DEVELOPMENTS 234

TABLE 252 CLINICAL TRIALS MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020) 234

12 COMPANY PROFILES 235

12.1 KEY COMPANIES 235

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

12.1.1 IQVIA 235

TABLE 253 IQVIA: BUSINESS OVERVIEW 235

FIGURE 49 IQVIA: COMPANY SNAPSHOT 236

TABLE 254 IQVIA: SERVICE OFFERINGS 236

TABLE 255 IQVIA: SERVICE LAUNCHES 237

TABLE 256 IQVIA: DEALS 238

TABLE 257 IQVIA: OTHER DEVELOPMENTS 238

12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE) 240

TABLE 258 LABCORP: BUSINESS OVERVIEW 240

FIGURE 50 LABCORP: COMPANY SNAPSHOT 241

TABLE 259 LABCORP: SERVICE OFFERINGS 241

TABLE 260 LABCORP: SERVICE LAUNCHES 242

TABLE 261 LABCORP: DEALS 243

TABLE 262 LABCORP: EXPANSIONS 244

12.1.3 SYNEOS HEALTH INC. 246

TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 246

FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT 246

TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS 247

TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES 248

TABLE 266 SYNEOS HEALTH INC.: DEALS 248

12.1.4 WUXI APPTEC 252

TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW 252

FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT 253

TABLE 268 WUXI APPTEC: SERVICE OFFERINGS 253

TABLE 269 WUXI APPTEC: SERVICE LAUNCHES 255

TABLE 270 WUXI APPTEC: DEALS 256

TABLE 271 WUXI APPTEC: EXPANSIONS 257

12.1.5 CHARLES RIVER LABORATORIES 259

TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 259

FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 260

TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS 260

TABLE 274 CHARLES RIVER LABORATORIES: DEALS 261

TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS 263

12.1.6 PAREXEL INTERNATIONAL 265

TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW 265

TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS 265

TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES 267

TABLE 279 PAREXEL INTERNATIONAL: DEALS 268

TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS 270

12.1.7 PRA HEALTH SCIENCES 271

TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW 271

FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT 272

TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS 272

TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES 272

TABLE 284 PRA HEALTH SCIENCES: DEALS 273

TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS 274

12.1.8 PPD INC 275

TABLE 286 PPD INC: BUSINESS OVERVIEW 275

FIGURE 55 PPD INC: COMPANY SNAPSHOT 276

TABLE 287 PPD INC: SERVICE OFFERINGS 276

TABLE 288 PPD: SERVICE LAUNCHES 277

TABLE 289 PPD: DEALS 278

TABLE 290 PPD: EXPANSIONS 280

12.1.9 ICON PLC 281

TABLE 291 ICON PLC: BUSINESS OVERVIEW 281

FIGURE 56 ICON PLC: COMPANY SNAPSHOT 281

TABLE 292 ICON PLC: SERVICE OFFERINGS 282

TABLE 293 ICON PLC : SERVICE LAUNCHES 285

TABLE 294 ICON PLC: DEALS 285

12.1.10 MEDPACE HOLDINGS INC 287

TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW 287

FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT 287

TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS 288

TABLE 297 MEDPACE HOLDINGS INC: DEALS 288

TABLE 298 MEDPACE HOLDINGS INC: EXPANSION 288

12.1.11 ACM GLOBAL LABORATORIES 289

TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW 289

TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS 289

12.1.12 ADVANCED CLINICAL 291

TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW 291

TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS 291

12.1.13 SGS 293

TABLE 303 SGS: BUSINESS OVERVIEW 293

FIGURE 58 SGS: COMPANY SNAPSHOT 294

TABLE 304 SGS: SERVICE OFFERINGS 294

TABLE 305 SGS: DEALS 295

12.1.14 FRONTAGE HOLDINGS CORPORATION 296

TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW 296

FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT 297

TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS 297

TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS 298

TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION 299

12.1.15 PSI CRO AG 300

TABLE 310 PSI CRO AG: BUSINESS OVERVIEW 300

TABLE 311 PSI CRO AG: SERVICE OFFERINGS 300

TABLE 312 PSI CRO AG: EXPANSIONS 300

12.1.16 BIO AGILE THERAPEUTICS 301

TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW 301

TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS 301

*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.

12.2 OTHER PLAYERS 303

12.2.1 AZELIX 303

TABLE 315 AZELIX: COMPANY OVERVIEW 303

12.2.2 CTSERV 304

TABLE 316 CTSERV: COMPANY OVERVIEW 304

12.2.3 PEPGRA 304

TABLE 317 PEPGRA: COMPANY OVERVIEW 304

12.2.4 AXCENT ADVANCED ANALYTICS (A3) 305

TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW 305

12.2.5 DOVE QUALITY SOLUTIONS 306

TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW 306

12.2.6 FIRMA CLINICAL RESEARCH 306

TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW 306

12.2.7 CELERION 307

TABLE 321 CELERION: COMPANY OVERVIEW 307

12.2.8 NOVOTECH HEALTH HOLDINGS 308

TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW 308

12.2.9 GENETICIST INC. 308

TABLE 323 GENETICIST INC.: COMPANY OVERVIEW 308

12.2.10 LINICAL AMERICAS 309

TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW 309

13 APPENDIX 310

13.1 DISCUSSION GUIDE 310

13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 313

13.3 AVAILABLE CUSTOMIZATIONS 315

13.4 RELATED REPORT 316

13.5 AUTHOR DETAILS 317

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（clinical trial）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

臨床試験市場：フェーズ（フェーズI、II、III）、サービスタイプ（施設確認、ラボサービス、分散型臨床試験）、治療領域（腫瘍、感染症）、アプリケーション（ワクチン、細胞・遺伝子治療）別 - 2026年までの世界予測

サマリー

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（clinical trial）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?